Search

Displaying results 2781 - 2790 of 2817 in total
  1. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    Taletrectinib is an orally available small molecule kinase inhibitor. It is targeted against ROS1, including resistant mutant forms, and shows some inhibitor activity against tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC. Gene...

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  2. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-produc...

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  3. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. By b...

    Categories: Cytochrome P-450 CYP3A Inhibitors, P-glycoprotein substrates
  5. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader. It was identified through a targeted medicinal chemistry optimization campaign to act as...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 Inhibitors
  6. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer. It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that ar...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Hydrastinine

    go.drugbank.com/drugs/DB19359
    Experimental

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Da...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  9. Drug

    N,N-dimethylformamide

    go.drugbank.com/drugs/DB01844
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates
  10. Drug

    Epothilone D

    go.drugbank.com/drugs/DB01873
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors